{
  "item1": "Thrombectomy Catheters treat deep vein thrombosis, EKOS™ Ultrasound Assisted Thrombolysis systems used treat pulmonary embolisms Varithena™ Polidocanol Injectable Foam used improve symptoms superficial venous incompetence appearance visible varicosities. interventional oncology embolization product offerings include following: TheraSphere™ Y-90 radioactive glass microspheres used treatment hepatocellular carcinoma (HCC), most common type liver cancer, Renegade™ HI-FLO™ Microcatheter Fathom™ Guidewire System Interlock™ - 35 Fibered IDC™ Interlock™ - 18 Fibered IDC™ Occlusion System peripheral embolization, EMBOLD™ Detachable Coil System, used arterial venous embolizations peripheral vasculature ICEFX™ Visual ICE™ Cryoablation Systems destruction tissue, using image-guided needles enable cryoablation visualization optimal tumor coverage third quarter 2024, completed acquisition Silk Road Medical, Inc. (Silk Road Medical), publicly traded medical device company developed innovative platform products prevent stroke patients carotid artery disease through minimally-invasive procedure called transcarotid artery revascularization. encounter significant competition across product lines each market which sell products solutions, some companies may greater financial, sales marketing resources than do.",
  "item7": "2022, amounts reflect sales reserves established Italian government payback provisions, not allocated reportable segments, which being disputed Italian court system. further discussion net sales comparison 2024 2023 net sales. 2023, generated net sales $14.240 billion compared $12.682 billion 2022. increase $1.558 billion, 12.3 percent, included operational growth 13.1 percent negative impact 80 basis points foreign currency fluctuations.",
  "item2": "part strategic imperative drive global expansion, seeking grow net sales market share expanding global presence, including Emerging Markets. Emerging Markets countries include all countries except United States, Western Central Europe, Japan, Australia, New Zealand Canada. Emerging Markets' net sales represented 15 percent consolidated net sales during third quarter first nine months 2025, respectively, 16 percent 17 percent during third quarter first nine months 2024, respectively. During third quarter 2025, Emerging Markets net sales grew 11.8 percent reported basis, which included operational net sales growth 11.5 percent positive impact 20 basis points foreign currency fluctuations, compared prior year period."
}